Quick Answer: Is There a Vaccine for Prostate Cancer?
Yes—but it is a treatment vaccine, not a vaccine that prevents prostate cancer.
Sipuleucel-T (Provenge) is an FDA-approved personalized cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
It has been FDA-approved since 2010, so it is no longer an experimental treatment. It is made from a patient’s own immune cells, which are collected, activated against a prostate-cancer-associated antigen, and then infused back into the patient.
Provenge is not suitable for every man with prostate cancer. It is not used to prevent prostate cancer, is not a standard treatment for localized early-stage disease, and is not routinely given after prostate surgery or radiotherapy.
What Does “Prostate Cancer Vaccine” Mean?
Most familiar vaccines—such as measles or influenza vaccines—are designed to prevent an infection before it occurs.
Cancer treatment vaccines work differently.
The National Cancer Institute defines cancer treatment vaccines as a form of immunotherapy that helps the immune system recognize antigens associated with cancer cells and mount an immune response against them.
They are given to people who already have cancer.
What Is Sipuleucel-T (Provenge)?
Sipuleucel-T, sold under the brand name Provenge, is an autologous cellular immunotherapy.
“Autologous” means the treatment is made using the individual patient’s own cells.
FDA approved Provenge in 2010 for:
asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
This means the cancer:
- has spread beyond the prostate;
- continues to progress despite testosterone being suppressed to castrate levels; and
- is causing no symptoms or only relatively mild symptoms.
See our advanced prostate cancer guide for the broader treatment framework.
Is Provenge a Dendritic-Cell Vaccine?
It is sometimes described this way, but the FDA terminology is more precise.
During manufacture, immune cells are collected by leukapheresis. The product contains antigen-presenting cells (APCs) together with other immune cells including T cells, B cells and natural-killer cells.
The collected cells are exposed to a recombinant protein called PAP-GM-CSF, which combines:
- prostatic acid phosphatase (PAP) — an antigen expressed in prostate-cancer tissue; and
- GM-CSF — an immune-cell activator.
The activated patient-specific cellular product is then returned by intravenous infusion.
How Is Provenge Treatment Given?
The complete course consists of three doses.
Each dose requires its own leukapheresis procedure.
| Step | What happens? |
|---|---|
| 1. Leukapheresis | Immune cells are collected from the patient’s blood. |
| 2. Cell processing | The collected cells are shipped to a manufacturing facility and exposed to PAP-GM-CSF. |
| 3. Return to clinic | The patient-specific product is returned approximately 3 days later. |
| 4. IV infusion | Provenge is infused intravenously over approximately 1 hour. |
| 5. Repeat | The process is completed for 3 total doses, generally about 2 weeks apart. |
Because each treatment is manufactured specifically for one patient, appointments need to be coordinated carefully.
Who Is a Candidate for Provenge?
The FDA indication is deliberately narrow.
A typical candidate has:
- metastatic prostate cancer;
- castration-resistant disease;
- testosterone already suppressed by ongoing androgen deprivation therapy;
- no cancer-related symptoms or only mild symptoms; and
- sufficient health to undergo leukapheresis and repeated infusions.
It is generally considered earlier in the mCRPC treatment course rather than waiting until a patient has severe cancer-related symptoms or rapidly progressive visceral disease.
Who Is Provenge Not Intended For?
Provenge is not FDA-approved as routine treatment for:
- men who do not have prostate cancer;
- prostate-cancer prevention;
- localized low-risk prostate cancer;
- routine use after prostatectomy;
- routine use after radiotherapy;
- hormone-sensitive metastatic disease under its traditional FDA indication; or
- patients whose major clinical problem is rapidly progressive, severely symptomatic disease requiring a faster-acting treatment strategy.
Current treatment selection must also account for other available life-prolonging options such as ARPIs, chemotherapy, PARP inhibitors, radioligand therapy and radium-223.
See our prostate cancer drugs overview.
Does Provenge Improve Survival?
Yes, in the population studied in the pivotal IMPACT trial.
In that randomized phase III study:
- median overall survival was 25.8 months with sipuleucel-T;
- median overall survival was 21.7 months with control treatment; and
- the relative risk of death was reduced by approximately 22%.
The difference in median overall survival was approximately 4.1 months.
However, the treatment did not significantly delay conventional objective disease progression.
Will Provenge Make PSA Fall?
Not necessarily.
One unusual feature of sipuleucel-T is that its survival benefit does not always correspond to a dramatic PSA decline or obvious early tumour shrinkage.
Therefore, patients should not assume treatment has failed simply because PSA does not rapidly fall after the three infusions.
Ongoing disease monitoring remains necessary.
Is Provenge a Cure?
No.
Sipuleucel-T is a life-prolonging therapy for selected metastatic castration-resistant prostate cancer.
It does not eradicate advanced metastatic disease, and patients usually continue androgen deprivation and may later receive additional systemic therapies.
Does ADT Continue During or After Provenge?
Yes.
In castration-resistant prostate cancer, androgen deprivation is generally continued to keep testosterone suppressed.
Provenge is an additional therapy rather than a replacement for ongoing ADT.
What Are the Common Side Effects?
Current prescribing information lists the most common adverse reactions—reported in at least 15% of treated patients—as:
- chills;
- fatigue;
- fever;
- back pain;
- nausea;
- joint aches; and
- headache.
Many occur around the time of infusion.
Acute Infusion Reactions
Infusion reactions occurring within one day can include:
- chills/rigors;
- fever;
- fatigue;
- nausea or vomiting;
- headache;
- muscle aches;
- shortness of breath;
- low oxygen levels;
- bronchospasm;
- low or high blood pressure;
- fast heartbeat;
- dizziness; and
- fainting.
Patients are generally premedicated with acetaminophen/paracetamol and an antihistamine before infusion to reduce acute reactions.
Blood Clots and Vascular Events
Thromboembolic events including:
- deep-vein thrombosis; and
- pulmonary embolism
have been reported after Provenge.
Stroke/TIA and myocardial infarction have also been reported. Current labeling states that the exact causal relationship is uncertain because many affected patients already had cardiovascular or clotting risk factors.
- new one-sided weakness or numbness;
- difficulty speaking;
- sudden vision change;
- new one-sided leg swelling/pain;
- sudden breathlessness;
- chest pain; or
- collapse/fainting.
Risks From Leukapheresis and Venous Access
Because the patient’s immune cells must be collected before every dose, treatment also involves the risks of leukapheresis.
Some men have adequate peripheral veins. Others may require a central venous catheter.
A catheter can introduce additional risks including:
- infection;
- bleeding;
- thrombosis; and
- catheter complications.
Fever or redness/pain around a catheter or collection site should be reported.
What Happened to PROSTVAC?
The legacy version of this page described PROSTVAC-VF as another promising prostate-cancer vaccine in early development.
That information is now outdated.
PROSTVAC used recombinant vaccinia and fowlpox viral vectors carrying PSA-related antigens to stimulate an anti-tumour immune response.
Early phase II results appeared encouraging.
However, the large randomized phase III trial was stopped for futility.
It found:
- median overall survival of 34.4 months with PROSTVAC;
- 34.3 months with placebo; and
- no significant improvement in overall survival.
The investigators concluded that PROSTVAC was generally well tolerated but did not improve survival or the six-month event-free endpoint.
What About DNA Vaccines for Prostate Cancer?
The old page refers to an experimental DNA vaccine investigated by researchers in Ireland.
That was an early research concept, not an approved therapy.
DNA vaccines, peptide vaccines, viral-vector vaccines and other therapeutic vaccine strategies have continued to be investigated, often in combination with:
- immune-checkpoint inhibitors;
- androgen-receptor-targeted drugs;
- radiotherapy;
- other immunotherapies; or
- novel immune-stimulating agents.
But experimental vaccine platforms should not be presented alongside Provenge as though they have the same evidence or regulatory status.
Are Checkpoint Inhibitors Prostate Cancer Vaccines?
No.
Checkpoint inhibitors such as pembrolizumab are another type of immunotherapy.
They remove inhibitory signals that restrain immune cells, rather than vaccinating the immune system against a specific prostate antigen.
Checkpoint inhibitors have a limited role in unselected prostate cancer but can be particularly relevant in uncommon molecular subgroups such as MSI-high or mismatch-repair-deficient cancers.
Provenge vs Other Modern mCRPC Treatments
| Treatment type | Example | How selection differs |
|---|---|---|
| Cellular immunotherapy | Sipuleucel-T | Best-established for asymptomatic/minimally symptomatic mCRPC. |
| AR pathway therapy | Abiraterone, enzalutamide | Choice depends heavily on previous hormonal therapy and cross-resistance. |
| Chemotherapy | Docetaxel, cabazitaxel | Useful when cytotoxic treatment is appropriate; often favored with more aggressive/symptomatic disease. |
| PARP-directed therapy | Olaparib and others | Requires relevant HRR/BRCA genomic context depending on indication. |
| PSMA radioligand therapy | Lu-177 PSMA / Pluvicto | Requires appropriate PSMA-positive disease and treatment setting. |
| Bone-targeting radiopharmaceutical | Radium-223 | Selected bone-predominant disease without inappropriate visceral disease. |
Current EAU guidance includes sipuleucel-T among life-prolonging systemic treatment options for mCRPC, with selection based on symptoms, previous treatment, comorbidities, metastatic pattern, genomic profile and patient preference.
Is Provenge Available Everywhere?
Availability varies considerably by country and healthcare system.
FDA approval applies to the United States. Access, reimbursement and regulatory status can differ elsewhere.
Patients should ask their oncology team whether sipuleucel-T is available and clinically appropriate in their country.
Questions to Ask Your Oncologist About Provenge
- Is my cancer metastatic and castration-resistant?
- Do I fit the asymptomatic/minimally symptomatic population in which Provenge is approved?
- What other mCRPC treatments have I already received?
- Would I benefit more from Provenge now or from another systemic therapy first?
- Do I have adequate venous access for leukapheresis?
- What cardiovascular or clotting risks do I have?
- Will I continue ADT during Provenge treatment?
- How will my cancer be monitored if PSA does not fall?
- What treatment is likely to come after Provenge?
- Are there any appropriate clinical trials for other immunotherapy approaches?
The term “prostate cancer vaccine” can easily create the wrong expectation. Provenge does not prevent prostate cancer, and it is not a routine vaccine given to healthy men. It is a personalized immune-cell treatment for a selected group of men who already have metastatic castration-resistant prostate cancer.
Another important point is that Provenge may improve overall survival without producing the dramatic PSA fall or immediate tumour shrinkage that patients often expect from cancer treatment. Its benefit therefore needs to be understood in the context of the clinical trial evidence rather than judged from one early PSA result.
I would also distinguish Provenge from experimental vaccine approaches. PROSTVAC is a good example: early studies looked promising, but the later phase III trial failed to show a survival benefit. That is why phase III evidence and regulatory approval matter before describing a treatment as established.
Dr. Albana Greca, MD, MMedSc
Family Physician / General Practitioner
Founder & Lead Medical Author, Prostate Treatment Options
Medical References
U.S. Food and Drug Administration. Provenge (sipuleucel-T): indication for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer and product information.
DailyMed / U.S. Prescribing Information. Provenge (sipuleucel-T): three-dose treatment course, leukapheresis, infusion reactions, thromboembolic/vascular warnings and common adverse effects.
National Cancer Institute. Cancer Treatment Vaccines: therapeutic vaccines versus preventive vaccines and sipuleucel-T cellular immunotherapy.
Kantoff PW et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med. 2010;363:411–422.
Gulley JL et al. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic mCRPC. J Clin Oncol. 2019: no overall-survival benefit.
European Association of Urology. Prostate Cancer Guidelines, 2026: systemic treatment options for metastatic castration-resistant prostate cancer.
Last evidence update: September 2026.
Medical information notice: Sipuleucel-T is a specialist cancer treatment for a narrow advanced-disease indication. Treatment selection must be individualized by an oncology/urology team based on symptoms, prior therapy, disease burden, comorbidities and available alternatives.